A Phase I Clinical Trial Assessing Intravesical Antisense Oligonucleotide Targeting Heat Shock Protein 27 for the Treatment of Superficial Bladder Cancer.

Trial Profile

A Phase I Clinical Trial Assessing Intravesical Antisense Oligonucleotide Targeting Heat Shock Protein 27 for the Treatment of Superficial Bladder Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Apatorsen (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 10 May 2016 Status changed from recruiting to completed, as per an abstract presented at the 111th Annual Meeting of the American Urological Association
    • 10 May 2016 Results presented at the 111th Annual Meeting of the American Urological Association
    • 09 Feb 2012 Planned end date changed from 1 Apr 2017 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top